SGLT2 inhibitor use, in addition to guideline-directed medical therapy, reduced heart failure exacerbations, all-cause mortality, and adverse renal outcomes in patients who already had cancer therapy-related cardiac dysfunction or heart failure at baseline [29]. The gene discussed is SLC5A2; the disease is heart failure.